Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. Lyke, KE; Atmar, RL; Dominguez Islas, C; Posavad, CM; Deming, ME; Branche, AR; Johnston, C; El Sahly, HM; Edupuganti, S; Mulligan, MJ; Stanford, A; Suthar, MS; Wald, A; Whitaker, JA. npj Vaccines. 2023; 8:98.

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Lyke, KE; Atmar, RL; Islas, CD; Posavad, CM; Szydlo, D; Paul Chourdhury, R; Deming, ME; Eaton, A; Jackson, LA; Branche, AR; Moore, KM; Manning, K; Foster, SL; Patel, M. Cell Reports Medicine. 2022; 3:100679.

Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Ortiz, JR; Spearman, PW; Goepfert, PA; Cross, K; Buddy Creech, C; Chen, WH; Parker, S; Overton, ET; Dickey, M; Logan, HL; Wegel, A; Neuzil, KM. Vaccine. 2022; 40:3253-3262.

Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. Frenck, RW; Conti, V; Ferruzzi, P; Ndiaye, AG W; Parker, S; McNeal, MM; Dickey, M; Granada, JP; Cilio, GL; De Ryck, I; Rappuoli, R; Saul, A; Martin, LB; Podda, A. EClinicalMedicine. 2021; 39:101076.

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Scaggs Huang, F; Bernstein, DI; Slobod, KS; Portner, A; Takimoto, T; Russell, CJ; Meagher, M; Jones, BG; Sealy, RE; Coleclough, C; McNeal, M; Makowski, M; Nakamura, A; Hurwitz, JL. Human Vaccines and Immunotherapeutics. 2021; 17:554-559.

Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; McNeal, M; Detizio, K; Parker, S; Hoeper, A; Bourgeois, AL; Porter, CK; Venkatesan, MM; Kaminski, RW. mSphere. 2020; 5.

Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; McNeal, M; Lynen, A; Parker, S; Hoeper, A; Mani, S; Fix, A; Maier, N; Venkatesan, MM; Porter, CK. mSphere. 2020; 5.

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Bernstein, DI; Guptill, J; Naficy, A; Nachbagauer, R; Berlanda-Scorza, F; Feser, J; Wilson, PC; Solorzano, A; Van der Wielen, M; Walter, EB; Innis, BL; Garcia-Sastre, A; Palese, P; Krammer, F. The Lancet Infectious Diseases. 2020; 20:80-91.